The management of lamivudine resistance in inununocompromised chronic hepatitis B liver transplantation recipient under immunosuppressant therapy
- VernacularTitle:乙肝患者肝移植术后免疫抑制治疗下拉米夫定耐药的发生和治疗
- Author:
Shuhong YI
;
Changjie CAI
;
Minqiang LU
;
Yang YANG
;
Hua LI
;
Chi XU
;
Huimin YI
;
Genshu WANG
;
Guihua CHEN
- Publication Type:Journal Article
- Keywords:
Liver transplantation;
Hepatitis B;
Lamivudine
- From:
Chinese Journal of General Surgery
2000;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the occurrence and treatment of lamivudine resistance in immunocompromised chronic hepatitis B liver transplantation recipient. Methods From Oct 2003 to Mar 2005, 157 chronic hepatitis B liver recipients were analyzed retrospectively to investigate the occurrence and treatment of lamivudine resistant chronic hepatitis B. Results Ten (6. 37% ) cases developed resistance to lamivudine within 1 year after liver transplantation. These patients were treated subsequently with Adefovir dipivoxil or Entecavir. The mean reduction in HBV DNA levels at weeks 12,24,48 was(3. 85?0. 79)、(3. 27?0.84)、(3. 19?0.58) and 3,4,5 cases achieved HBV DNA
